The Milken Institute and Ann Theodore Foundation: Sarcoidosis Inhibitor of mTOR (SIM) Trial
Research Admin Offices:
- HRS
Funding Type:
GrantOpportunity Type:
- Grant
Value:
Up to $575,000 US over two years.
Disciplines:
- Health Sciences
Sponsors:
- Milken Institute
Deadlines:
Internal Deadline:
April 6, 2026Sponsor Deadline:
April 20, 2026Description:
This opportunity supports two-year investigator-initiated clinical trials that will test the efficacy of mTOR inhibitors in treating cutaneous sarcoidosis. This trial would be considered an early Phase 2 trial and would provide scientific support for a future Phase 2b/3 or a Phase 3 trial.
Resources:
Contact:
If applying from the Faculty of Health Sciences, unless otherwise indicated, you no longer need to send documents to HRS Intake. Your first point of contact is your assigned Senior Grants Advisor.